# Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer

> **NCT05705466** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Kartos Therapeutics, Inc.**

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Navtemadlin
- **DRUG:** Navtemadlin Placebo
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05705466
- **Lead sponsor:** Kartos Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06
- **Primary completion:** 2025-06
- **Final completion:** 2027-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05705466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05705466, "Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05705466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*